ArticleNeurology. Clinical practice2020
Visual tests predict dementia risk in Parkinson disease.
Open access · hybridAbstract read
In one paragraph
Article in Neurology. Clinical practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.8field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 55 citations in OpenAlex.
- Article
- Cortical α-synuclein pathology induces cell autonomous neuronal hypoactivity and compensatory circuit changes in a model of early Lewy body dementia.bioRxiv : the preprint server for biology · 2025Article
- Amygdala Neurodegeneration: A Key Driver of Visual Dysfunction in Parkinson's Disease.Annals of clinical and translational neurology · 2025Article
- Idiopathic Parkinson's Disease and Neuro-ophthalmological Findings: A Study on Neurodegeneration in the Retinal Nerve Fiber Layer and Cognitive Functions.Noro psikiyatri arsivi · 2025Article
- Aggregation-resistant alpha-synuclein tetramers are reduced in the blood of Parkinson's patients.EMBO molecular medicine · 2024Article
- Sensory Loss and Risk of Dementia.The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry · 2024Review
- Longitudinal Associations of Magnetic Susceptibility with Clinical Severity in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2024Article
- Visual processing speed and its association with future dementia development in a population-based prospective cohort: EPIC-Norfolk.Scientific reports · 2024Article
- Association of retinal neurodegeneration with the progression of cognitive decline in Parkinson's disease.NPJ Parkinson's disease · 2024Article
- Visual dysfunction is a better predictor than retinal thickness for dementia in Parkinson's disease.Journal of neurology, neurosurgery, and psychiatry · 2023Article
- Visual Dysfunction in Parkinson's Disease.Brain sciences · 2023Review
- Multicohort cross-sectional study of cognitive and behavioural digital biomarkers in neurodegeneration: the Living Lab Study protocol.BMJ open · 2023Article
- Structural and functional changes in the retina in Parkinson's disease.Journal of neurology, neurosurgery, and psychiatry · 2023Review
- Changes in both top-down and bottom-up effective connectivity drive visual hallucinations in Parkinson's disease.Brain communications · 2023Article
- Brain Networks Involved in Depression in Patients with Frontotemporal Dementia and Parkinson's Disease: An Exploratory Resting-State Functional Connectivity MRI Study.Diagnostics (Basel, Switzerland) · 2022Article
- Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease.Nature reviews. Neurology · 2022Review
- Circumpapillary Retinal Nerve Fiber Layer OCT Imaging in a Parkinson's Disease Cohort-A Multidisciplinary Approach in a Clinical Research Hospital.Journal of personalized medicine · 2022Article
- Ophthalmologic problems correlates with cognitive impairment in patients with Parkinson's disease.Frontiers in neuroscience · 2022Article
- Visual Dysfunction Predicts Cognitive Impairment and White Matter Degeneration in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2021Article
- Sequence of clinical and neurodegeneration events in Parkinson's disease progression.Brain : a journal of neurology · 2021Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Louise-Ann LeylandDementia Research Centre (L-AL, RM, RSW), Institute of Neurology, University College London, United Kingdom; Neuro-ophthalmology (FDB, MM-ML), National Hospital for Neurology and Neurosurgery, University College London Hospitals, London, United Kingdom; Institute of Neurology (SH, MD, MREC), University College London, UCL, United Kingdom; School of Biomedical Sciences (MREC), Biological Sciences, Leeds University, United Kingdom; ImpAct (LEM), Lyon Neuroscience Research Center, France; Department of Cognitive Science (APS), University of California, San Diego; Kavli Institute for Brain and Mind (APS), University of California, San Diego; Institute of Ophthalmology (PAK), UCL, United Kingdom; Moorfields Eye Hospital (PAK), London, United Kingdom; Department of Clinical Neuroscience (AES), Institute of Neurology, UCL Hampstead Campus, London, United Kingdom; Movement Disorders Consortium (AES, RSW), UCL, United Kingdom; and The Wellcome Centre for Human Neuroimaging (RSW), Institute of Neurology, University College London, United Kingdom.
Fion D BremnerDementia Research Centre (L-AL, RM, RSW), Institute of Neurology, University College London, United Kingdom; Neuro-ophthalmology (FDB, MM-ML), National Hospital for Neurology and Neurosurgery, University College London Hospitals, London, United Kingdom; Institute of Neurology (SH, MD, MREC), University College London, UCL, United Kingdom; School of Biomedical Sciences (MREC), Biological Sciences, Leeds University, United Kingdom; ImpAct (LEM), Lyon Neuroscience Research Center, France; Department of Cognitive Science (APS), University of California, San Diego; Kavli Institute for Brain and Mind (APS), University of California, San Diego; Institute of Ophthalmology (PAK), UCL, United Kingdom; Moorfields Eye Hospital (PAK), London, United Kingdom; Department of Clinical Neuroscience (AES), Institute of Neurology, UCL Hampstead Campus, London, United Kingdom; Movement Disorders Consortium (AES, RSW), UCL, United Kingdom; and The Wellcome Centre for Human Neuroimaging (RSW), Institute of Neurology, University College London, United Kingdom.
Ribeya MahmoodDementia Research Centre (L-AL, RM, RSW), Institute of Neurology, University College London, United Kingdom; Neuro-ophthalmology (FDB, MM-ML), National Hospital for Neurology and Neurosurgery, University College London Hospitals, London, United Kingdom; Institute of Neurology (SH, MD, MREC), University College London, UCL, United Kingdom; School of Biomedical Sciences (MREC), Biological Sciences, Leeds University, United Kingdom; ImpAct (LEM), Lyon Neuroscience Research Center, France; Department of Cognitive Science (APS), University of California, San Diego; Kavli Institute for Brain and Mind (APS), University of California, San Diego; Institute of Ophthalmology (PAK), UCL, United Kingdom; Moorfields Eye Hospital (PAK), London, United Kingdom; Department of Clinical Neuroscience (AES), Institute of Neurology, UCL Hampstead Campus, London, United Kingdom; Movement Disorders Consortium (AES, RSW), UCL, United Kingdom; and The Wellcome Centre for Human Neuroimaging (RSW), Institute of Neurology, University College London, United Kingdom.
Sam HewittDementia Research Centre (L-AL, RM, RSW), Institute of Neurology, University College London, United Kingdom; Neuro-ophthalmology (FDB, MM-ML), National Hospital for Neurology and Neurosurgery, University College London Hospitals, London, United Kingdom; Institute of Neurology (SH, MD, MREC), University College London, UCL, United Kingdom; School of Biomedical Sciences (MREC), Biological Sciences, Leeds University, United Kingdom; ImpAct (LEM), Lyon Neuroscience Research Center, France; Department of Cognitive Science (APS), University of California, San Diego; Kavli Institute for Brain and Mind (APS), University of California, San Diego; Institute of Ophthalmology (PAK), UCL, United Kingdom; Moorfields Eye Hospital (PAK), London, United Kingdom; Department of Clinical Neuroscience (AES), Institute of Neurology, UCL Hampstead Campus, London, United Kingdom; Movement Disorders Consortium (AES, RSW), UCL, United Kingdom; and The Wellcome Centre for Human Neuroimaging (RSW), Institute of Neurology, University College London, United Kingdom.ORCID 0000-0002-9219-6324
Marion DurtesteDementia Research Centre (L-AL, RM, RSW), Institute of Neurology, University College London, United Kingdom; Neuro-ophthalmology (FDB, MM-ML), National Hospital for Neurology and Neurosurgery, University College London Hospitals, London, United Kingdom; Institute of Neurology (SH, MD, MREC), University College London, UCL, United Kingdom; School of Biomedical Sciences (MREC), Biological Sciences, Leeds University, United Kingdom; ImpAct (LEM), Lyon Neuroscience Research Center, France; Department of Cognitive Science (APS), University of California, San Diego; Kavli Institute for Brain and Mind (APS), University of California, San Diego; Institute of Ophthalmology (PAK), UCL, United Kingdom; Moorfields Eye Hospital (PAK), London, United Kingdom; Department of Clinical Neuroscience (AES), Institute of Neurology, UCL Hampstead Campus, London, United Kingdom; Movement Disorders Consortium (AES, RSW), UCL, United Kingdom; and The Wellcome Centre for Human Neuroimaging (RSW), Institute of Neurology, University College London, United Kingdom.
Molly R E CartlidgeDementia Research Centre (L-AL, RM, RSW), Institute of Neurology, University College London, United Kingdom; Neuro-ophthalmology (FDB, MM-ML), National Hospital for Neurology and Neurosurgery, University College London Hospitals, London, United Kingdom; Institute of Neurology (SH, MD, MREC), University College London, UCL, United Kingdom; School of Biomedical Sciences (MREC), Biological Sciences, Leeds University, United Kingdom; ImpAct (LEM), Lyon Neuroscience Research Center, France; Department of Cognitive Science (APS), University of California, San Diego; Kavli Institute for Brain and Mind (APS), University of California, San Diego; Institute of Ophthalmology (PAK), UCL, United Kingdom; Moorfields Eye Hospital (PAK), London, United Kingdom; Department of Clinical Neuroscience (AES), Institute of Neurology, UCL Hampstead Campus, London, United Kingdom; Movement Disorders Consortium (AES, RSW), UCL, United Kingdom; and The Wellcome Centre for Human Neuroimaging (RSW), Institute of Neurology, University College London, United Kingdom.
Michelle M-M LaiDementia Research Centre (L-AL, RM, RSW), Institute of Neurology, University College London, United Kingdom; Neuro-ophthalmology (FDB, MM-ML), National Hospital for Neurology and Neurosurgery, University College London Hospitals, London, United Kingdom; Institute of Neurology (SH, MD, MREC), University College London, UCL, United Kingdom; School of Biomedical Sciences (MREC), Biological Sciences, Leeds University, United Kingdom; ImpAct (LEM), Lyon Neuroscience Research Center, France; Department of Cognitive Science (APS), University of California, San Diego; Kavli Institute for Brain and Mind (APS), University of California, San Diego; Institute of Ophthalmology (PAK), UCL, United Kingdom; Moorfields Eye Hospital (PAK), London, United Kingdom; Department of Clinical Neuroscience (AES), Institute of Neurology, UCL Hampstead Campus, London, United Kingdom; Movement Disorders Consortium (AES, RSW), UCL, United Kingdom; and The Wellcome Centre for Human Neuroimaging (RSW), Institute of Neurology, University College London, United Kingdom.
Luke E MillerDementia Research Centre (L-AL, RM, RSW), Institute of Neurology, University College London, United Kingdom; Neuro-ophthalmology (FDB, MM-ML), National Hospital for Neurology and Neurosurgery, University College London Hospitals, London, United Kingdom; Institute of Neurology (SH, MD, MREC), University College London, UCL, United Kingdom; School of Biomedical Sciences (MREC), Biological Sciences, Leeds University, United Kingdom; ImpAct (LEM), Lyon Neuroscience Research Center, France; Department of Cognitive Science (APS), University of California, San Diego; Kavli Institute for Brain and Mind (APS), University of California, San Diego; Institute of Ophthalmology (PAK), UCL, United Kingdom; Moorfields Eye Hospital (PAK), London, United Kingdom; Department of Clinical Neuroscience (AES), Institute of Neurology, UCL Hampstead Campus, London, United Kingdom; Movement Disorders Consortium (AES, RSW), UCL, United Kingdom; and The Wellcome Centre for Human Neuroimaging (RSW), Institute of Neurology, University College London, United Kingdom.
Ayse P SayginDementia Research Centre (L-AL, RM, RSW), Institute of Neurology, University College London, United Kingdom; Neuro-ophthalmology (FDB, MM-ML), National Hospital for Neurology and Neurosurgery, University College London Hospitals, London, United Kingdom; Institute of Neurology (SH, MD, MREC), University College London, UCL, United Kingdom; School of Biomedical Sciences (MREC), Biological Sciences, Leeds University, United Kingdom; ImpAct (LEM), Lyon Neuroscience Research Center, France; Department of Cognitive Science (APS), University of California, San Diego; Kavli Institute for Brain and Mind (APS), University of California, San Diego; Institute of Ophthalmology (PAK), UCL, United Kingdom; Moorfields Eye Hospital (PAK), London, United Kingdom; Department of Clinical Neuroscience (AES), Institute of Neurology, UCL Hampstead Campus, London, United Kingdom; Movement Disorders Consortium (AES, RSW), UCL, United Kingdom; and The Wellcome Centre for Human Neuroimaging (RSW), Institute of Neurology, University College London, United Kingdom.
Pearse A KeaneDementia Research Centre (L-AL, RM, RSW), Institute of Neurology, University College London, United Kingdom; Neuro-ophthalmology (FDB, MM-ML), National Hospital for Neurology and Neurosurgery, University College London Hospitals, London, United Kingdom; Institute of Neurology (SH, MD, MREC), University College London, UCL, United Kingdom; School of Biomedical Sciences (MREC), Biological Sciences, Leeds University, United Kingdom; ImpAct (LEM), Lyon Neuroscience Research Center, France; Department of Cognitive Science (APS), University of California, San Diego; Kavli Institute for Brain and Mind (APS), University of California, San Diego; Institute of Ophthalmology (PAK), UCL, United Kingdom; Moorfields Eye Hospital (PAK), London, United Kingdom; Department of Clinical Neuroscience (AES), Institute of Neurology, UCL Hampstead Campus, London, United Kingdom; Movement Disorders Consortium (AES, RSW), UCL, United Kingdom; and The Wellcome Centre for Human Neuroimaging (RSW), Institute of Neurology, University College London, United Kingdom.
Anette E SchragDementia Research Centre (L-AL, RM, RSW), Institute of Neurology, University College London, United Kingdom; Neuro-ophthalmology (FDB, MM-ML), National Hospital for Neurology and Neurosurgery, University College London Hospitals, London, United Kingdom; Institute of Neurology (SH, MD, MREC), University College London, UCL, United Kingdom; School of Biomedical Sciences (MREC), Biological Sciences, Leeds University, United Kingdom; ImpAct (LEM), Lyon Neuroscience Research Center, France; Department of Cognitive Science (APS), University of California, San Diego; Kavli Institute for Brain and Mind (APS), University of California, San Diego; Institute of Ophthalmology (PAK), UCL, United Kingdom; Moorfields Eye Hospital (PAK), London, United Kingdom; Department of Clinical Neuroscience (AES), Institute of Neurology, UCL Hampstead Campus, London, United Kingdom; Movement Disorders Consortium (AES, RSW), UCL, United Kingdom; and The Wellcome Centre for Human Neuroimaging (RSW), Institute of Neurology, University College London, United Kingdom.
Rimona S WeilDementia Research Centre (L-AL, RM, RSW), Institute of Neurology, University College London, United Kingdom; Neuro-ophthalmology (FDB, MM-ML), National Hospital for Neurology and Neurosurgery, University College London Hospitals, London, United Kingdom; Institute of Neurology (SH, MD, MREC), University College London, UCL, United Kingdom; School of Biomedical Sciences (MREC), Biological Sciences, Leeds University, United Kingdom; ImpAct (LEM), Lyon Neuroscience Research Center, France; Department of Cognitive Science (APS), University of California, San Diego; Kavli Institute for Brain and Mind (APS), University of California, San Diego; Institute of Ophthalmology (PAK), UCL, United Kingdom; Moorfields Eye Hospital (PAK), London, United Kingdom; Department of Clinical Neuroscience (AES), Institute of Neurology, UCL Hampstead Campus, London, United Kingdom; Movement Disorders Consortium (AES, RSW), UCL, United Kingdom; and The Wellcome Centre for Human Neuroimaging (RSW), Institute of Neurology, University College London, United Kingdom.
University College Hospital · GB
Funding
Department of Health CS-2014-14-023Medical Research Council MR/T019050/1Wellcome Trust 205167/Z/16/Z
Abstract
objectiveTo assess the role of visual measures and retinal volume to predict the risk of Parkinson disease (PD) dementia.
methodsIn this cohort study, we collected visual, cognitive, and motor data in people with PD. Participants underwent ophthalmic examination, retinal imaging using optical coherence tomography, and visual assessment including acuity and contrast sensitivity and high-level visuoperception measures of skew tolerance and biological motion. We assessed the risk of PD dementia using a recently described algorithm that combines age at onset, sex, depression, motor scores, and baseline cognition.
resultsOne hundred forty-six people were included in the study (112 with PD and 34 age-matched controls). The mean disease duration was 4.1 (±2·5) years. None of these participants had dementia. Higher risk of dementia was associated with poorer performance in visual measures (acuity: ρ = 0.29,
conclusionVisual measures and retinal structure in dopaminergic layers were related to risk of PD dementia. Our findings suggest that visual measures and retinal GCL and IPL volumes may be useful to predict the risk of dementia in PD.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.